Stephen Hill
Chief Executive Officer at Faraday Pharmaceuticals, Inc.
Profile
Stephen Anthony Hill is currently the Chief Executive Officer & Director at Faraday Pharmaceuticals, Inc. (Washington), as well as the Chief Executive Officer & Director at Faraday Pharmaceuticals, Inc. and Director at Resolys Bio, Inc. He previously served as President & Chief Executive Officer at Unimed Pharmaceuticals LLC, President, Chief Executive Officer & Director at ArQule, Inc., President & Chief Executive Officer at Solvay Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Targacept, Inc., President & Chief Executive Officer at 21st Century Biodefense, Inc., President & Chief Executive Officer at QUE Oncology, Inc., Chairman at Audeo Oncology, Inc., Chairman at Novelos Therapeutics, Inc., Lead Independent Director at Lipocine, Inc., and Independent Director at Cellectar Biosciences, Inc. He also served as Director at Catalyst Biosciences, Inc. He received his undergraduate and doctorate degrees from the University of Oxford and his undergraduate and doctorate degrees from St Catherine's College.
Stephen Hill active positions
| Companies | Position | Start |
|---|---|---|
Faraday Pharmaceuticals, Inc.
 Faraday Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Faraday Pharmaceuticals, Inc. engages in the research and development of elemental reducing agents (ERAs). Its therapeutic agents have potential applications for treatment of critical care illnesses. The company was founded by Mark B. Roth and Christopher Toombs in 2014 and is headquartered in Seattle, WA. | Chief Executive Officer | 01/08/2015 |
Faraday Pharmaceuticals, Inc. (Washington)
 Faraday Pharmaceuticals, Inc. (Washington) Drugstore ChainsRetail Trade Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA. | Chief Executive Officer | 01/08/2015 |
Resolys Bio, Inc.
 Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Resolys Bio, Inc. operates as a pharmaceutical company. The firm develops OSLO and MCC for the treatment of certain forms of traumatic brain injury and chronic painful tissue disorders. The company is headquartered in Delanson, NY. | Director/Board Member | 01/03/2020 |
Former positions of Stephen Hill
| Companies | Position | End |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chairman | 21/07/2015 |
| CATALYST BIOSCIENCES | Director/Board Member | 13/06/2019 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Chief Executive Officer | 01/08/2015 |
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Chairman | 12/02/2014 |
QUE Oncology, Inc.
 QUE Oncology, Inc. Pharmaceuticals: MajorHealth Technology QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA. | Chief Executive Officer | 01/11/2012 |
Training of Stephen Hill
| University of Oxford | Doctorate Degree |
| St Catherine's College | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| LIPOCINE INC. | Health Technology |
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Private companies | 13 |
|---|---|
Unimed Pharmaceuticals LLC
 Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Faraday Pharmaceuticals, Inc. (Washington)
Faraday Pharmaceuticals, Inc. (Washington) Drugstore ChainsRetail Trade Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA. | Retail Trade |
Audeo Oncology, Inc.
 Audeo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Audeo Oncology, Inc. used to provide cancer treatment services. It focused on utilizing its Hyaluronic Acid Chemotransport technology for cancer drugs and tumor cells to enhance drug activities. The company was founded on June 1, 2012 and was headquartered in San Francisco, CA. | Health Technology |
Solvay Pharmaceuticals, Inc.
 Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | Health Technology |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
| 21st Century Biodefense, Inc. | |
QUE Oncology, Inc.
QUE Oncology, Inc. Pharmaceuticals: MajorHealth Technology QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA. | Health Technology |
Faraday Pharmaceuticals, Inc.
Faraday Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Faraday Pharmaceuticals, Inc. engages in the research and development of elemental reducing agents (ERAs). Its therapeutic agents have potential applications for treatment of critical care illnesses. The company was founded by Mark B. Roth and Christopher Toombs in 2014 and is headquartered in Seattle, WA. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Resolys Bio, Inc.
Resolys Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Resolys Bio, Inc. operates as a pharmaceutical company. The firm develops OSLO and MCC for the treatment of certain forms of traumatic brain injury and chronic painful tissue disorders. The company is headquartered in Delanson, NY. | Commercial Services |
Hoffmann-La Roche Products Ltd.
 Hoffmann-La Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Hoffmann-La Roche Products Ltd. develops and manufactures pharmaceuticals and diagnostic solutions. The private company is based in Hamilton, Bermuda. | Health Technology |
- Stock Market
- Insiders
- Stephen Hill
